| Literature DB >> 31725737 |
Kanna Hayashi1,2, Lianping Ti1,3, Huiru Dong1,4, Brittany Bingham2,5, Andrew Day5, Ronald Joe5, Rolando Barrios5, Kora DeBeck1,6, M-J Milloy1,3, Thomas Kerr1,3.
Abstract
BACKGROUND: Urban drug scenes are characterized by high prevalence of illicit drug dealing and use, violence and poverty, much of which is driven by the criminalization of people who use illicit drugs (PWUD) and the associated stigma. Despite significant public health needs, little is understood about patterns of moving into urban drug scenes among PWUD. Therefore, we sought to identify trajectories of residential mobility (hereafter 'mobility') among PWUD into the Downtown Eastside (DTES), an urban neighbourhood with an open drug scene in Vancouver, Canada, as well as characterize distinct trajectory groups among PWUD.Entities:
Mesh:
Year: 2019 PMID: 31725737 PMCID: PMC6855692 DOI: 10.1371/journal.pone.0224993
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sample characteristics and bivariable multinomial logistic regression analyses of baseline factors associated with mobility trajectory groups among people who use drugs in Vancouver, Canada (n = 906).
| Characteristic | n (%) | Odds Ratio (95% CI) | ||
|---|---|---|---|---|
| Group 2: Gradual move to DTES | Group 3: Move in then out | Group 4: Early move to DTES | ||
| Age (median, IQR) | 30 (22–44) | n/a | n/a | n/a |
| 626 (69.1%) | n/a | n/a | n/a | |
| 247 (27.3%) | n/a | n/a | n/a | |
| 300 (33.1%) | 0.81 (0.54–1.22) | 0.80 (0.54–1.20) | 0.77 (0.49–1.22) | |
| 392 (43.3%) | 1.16 (0.80–1.69) | 0.98 (0.67–1.43) | 0.53 (0.34–0.84) | |
| 644 (71.1%) | 0.62 (0.42–0.92) | 0.80 (0.54–1.20) | 1.94 (1.12–3.38) | |
| Homeless | 273 (30.1%) | 1.77 (1.17–2.67) | 2.28 (1.48–3.51) | 1.31 (0.79–2.17) |
| SRO | 101 (11.2%) | 1.19 (0.58–2.42) | 3.76 (2.14–6.60) | 3.01 (1.64–5.55) |
| Other unstable housing | 41 (4.5%) | 0.58 (0.17–1.98) | 1.99 (0.85–4.68) | 1.62 (0.63–4.17) |
| Stable housing | 478 (52.8%) | reference | reference | reference |
| 82 (9.1%) | 1.08 (0.55–2.11) | 1.64 (0.92–2.95) | 1.07 (0.50–2.26) | |
| 306 (33.8%) | 1.50 (1.02–2.22) | 1.71 (1.17–2.51) | 1.43 (0.92–2.22) | |
| 138 (15.2%) | 2.50 (1.54–4.08) | 1.75 (1.04–2.95) | 3.16 (1.89–5.30) | |
| ≥Daily use | 117 (12.9%) | 1.53 (0.85–2.77) | 2.01 (1.16–3.49) | 3.39 (1.93–5.96) |
| <Daily use | 241 (26.6%) | 1.34 (0.87–2.06) | 1.41 (0.92–2.16) | 1.60 (0.97–2.63) |
| Not used | 542 (59.8%) | reference | reference | reference |
| ≥Daily use | 42 (4.6%) | 0.84 (0.28–2.53) | 1.55 (0.66–3.64) | 3.47 (1.59–7.61) |
| <Daily use | 146 (16.1%) | 1.37 (0.84–2.22) | 0.84 (0.48–1.46) | 1.67 (0.98–2.86) |
| Not used | 709 (78.3%) | reference | reference | reference |
| ≥Daily use | 224 (24.7%) | 1.08 (0.61–1.91) | 1.67 (0.90–3.09) | 2.65 (1.31–5.35) |
| <Daily use | 518 (57.2%) | 1.00 (0.61–1.64) | 1.59 (0.92–2.74) | 1.64 (0.85–3.18) |
| Not used | 163 (18.0%) | reference | reference | reference |
| ≥Daily use | 147 (16.2%) | 1.52 (0.87–2.64) | 2.08 (1.25–3.46) | 6.23 (3.39–11.46) |
| <Daily use | 363 (40.1%) | 0.91 (0.60–1.37) | 0.79 (0.52–1.20) | 2.44 (1.43–4.17) |
| Not used | 394 (43.5%) | reference | reference | reference |
| ≥Daily use | 97 (10.7%) | 0.92 (0.48–1.76) | 0.47 (0.21–1.06) | 0.59 (0.28–1.25) |
| <Daily use | 524 (57.8%) | 0.93 (0.61–1.42) | 1.10 (0.73–1.66) | 0.64 (0.41–1.00) |
| Not used | 283 (31.2%) | reference | reference | reference |
| 221 (24.4%) | 0.68 (0.43–1.09) | 0.72 (0.46–1.14) | 1.35 (0.86–2.14) | |
| Withdrawal management | 34 (3.8%) | 3.15 (1.34–7.40) | 2.40 (0.97–5.95) | 1.23 (0.34–4.41) |
| Other treatment/services | 174 (19.2%) | 1.13 (0.70–1.82) | 1.08 (0.67–1.73) | 1.20 (0.71–2.02) |
| Not used | 692 (76.4%) | reference | reference | reference |
| 774 (85.4%) | 1.22 (0.71–2.09) | 1.65 (0.92–2.95) | 1.51 (0.79–2.87) | |
| 79 (8.7%) | 1.27 (0.69–2.35) | 0.79 (0.39–1.62) | 0.87 (0.40–1.90) | |
| 231 (25.5%) | 0.36 (0.21–0.62) | 0.52 (0.32–0.83) | 1.17 (0.74–1.83) | |
| 443 (48.9%) | 0.76 (0.52–1.12) | 0.71 (0.48–1.03) | 3.06 (1.91–4.89) | |
| 465 (51.3%) | 0.68 (0.47–1.00) | 0.71 (0.49–1.03) | 0.80 (0.52–1.21) | |
| Median (IQR) | 2006 (2006–2009) | |||
| Per year later | 1.11 (1.01–1.23) | 1.07 (0.95–1.20) | 1.08 (0.96–1.21) | |
DTES: Downtown Eastside. HIV: human immunodeficiency virus. HCV: hepatitis C virus. IQR: interquartile range. OAT: opioid agonist therapy. SRO: single room occupancy hotel.
* Denotes behaviours and events in the previous six months assessed at baseline
Fig 1Four-group trajectories of moving into DTES, adjusting for baseline demographic characteristics (age, sex, and ethnicity).
Red: Consistently living outside of DTES (Group 1). Green: Gradual move into DTES (Group 2). Blue: Move in then out (Group 3). Black: Early move into DTES (Group 4).
Multivariable multinomial logistic regression analyses of baseline factors associated with mobility trajectory groups among people who use drugs in Vancouver, Canada (n = 906).
| Characteristic | Adjusted Odds Ratio (95% CI) | ||
|---|---|---|---|
| Group 2: Gradual move to DTES | Group 3: Move in then out | Group 4: Early move to DTES | |
| Homeless | 1.35 (0.84–2.17) | 1.88 (1.17–3.03) | 1.59 (0.87–2.89) |
| SRO | 1.52 (0.73–3.17) | 4.01 (2.19–7.37) | 3.40 (1.73–6.68) |
| Other unstable housing | 0.64 (0.18–2.27) | 2.25 (0.92–5.53) | 1.36 (0.46–4.03) |
| Stable housing | reference | reference | reference |
| 2.20 (1.29–3.74) | 1.55 (0.88–2.72) | 3.73 (2.08–6.70) | |
| ≥Daily use | 1.54 (0.80–2.97) | 2.64 (1.45–4.81) | 3.80 (1.84–7.82) |
| <Daily use | 1.08 (0.66–1.78) | 1.08 (0.66–1.77) | 1.61 (0.85–3.04) |
| Not used | reference | reference | reference |
| 0.49 (0.27–0.88) | 0.64 (0.37–1.11) | 1.07 (0.62–1.86) | |
| 0.91 (0.55–1.52) | 0.78 (0.48–1.29) | 2.30 (1.24–4.27) | |
DTES: Downtown Eastside. HIV: human immunodeficiency virus. HCV: hepatitis C virus. IQR: interquartile range. OAT: opioid agonist therapy. SRO: single room occupancy hotel.
* Denotes behaviours and events in the previous six months assessed at baseline